4'-hydroxydesazadesmethyldesferrithiocin | 220541-94-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4'-hydroxydesazadesmethyldesferrithiocin
• 英文别名: (S)-4,5-Dihydro-2-(2,4-dihydroxyphenyl)-4-thiazolecarboxylic acid；4,5-dihydro-2-(2,4-dihydroxyphenyl)-thiazole-4(S)-carboxylic acid；(4S)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid
• CAS: 220541-94-6
• 化学式: C₁₀H₉NO₄S
• 分子量: 239.252
• InChiKey: PWRDYSVMTCDMOD-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4'-hydroxydesazadesmethyldesferrithiocin 在 重水 作用下， 生成
  参考文献：
  名称：

  C-4立体化学和C-4'羟基化对去铁硫代类似物的铁清除效率和毒性的影响。

  摘要：

  进行了去铁硫霉素类似物的其他结构活性研究。使用对映体4,5-二氢-2-（2,4-二羟基苯基）噻唑-4（R）-羧酸和4,5对映体评估和评估C-4上立体化学对配体铁清除效率的影响-二氢-2-（2,4-二羟基苯基）噻唑-4（S）-羧酸。还通过4，5-二氢-2-（2-羟苯基）-4-甲基噻唑-4（S）的合成和体内比较进一步研究了4'-羟基化作为降低脱氮杂脱铁硫霉素类似物毒性的方法的实用性。 ）-羧酸，它是天然产物4-甲基芥子酸，和4，5-二氢-2-（2,4-二羟基苯基）-4-甲基噻唑-4（S）-羧酸。C-4处的立体化学显示对去铁硫代类似物的铁清除效率有实质性影响，C-4'-羟基化对毒性谱也有显着影响。所有化合物均在胆管插管的啮齿动物模型中进行评估，以确定铁清除效率，并将其运用于重载铁的灵长类动物中进行铁清除测试。根据当前工作的结果，尽管4,5-二氢-2-（2,4-二羟基苯基）噻唑-4（S）-羧酸仍然是临床评估中最有希望的候选药物，但是4

  DOI：

  10.1021/jm990058s
• 作为产物：
  描述：

  2,4-二羟基苯腈 、 D-半胱氨酸盐酸盐单水合物. 以 甲醇 、 碳酸氢钠 为溶剂， 以66%的产率得到4'-hydroxydesazadesmethyldesferrithiocin
  参考文献：
  名称：

  Iron binding agents

  摘要：

  本发明涉及一种用于治疗人类患有疟原虫感染的组合物、制品及方法。该方法包括给予化合物(I)或(IV)的治疗有效量，即足够减少疟原虫数量。本发明的组合物是一种含有药用辅料的化合物(I)或(IV)。制品是该组合物与用于治疗疟疾的标签的组合。取代基详见规范。

  公开号：

  US20030083349A1

文献信息

• Thiazoline acid derivatives
  申请人：University of Florida Research Foundation, Inc.

  公开号：US20030236417A1

  公开（公告）日：2003-12-25

  The present invention relates to novel thiazoline acids and derivatives thereof useful as chelators of trivalent metals in therapeutic applications. For example, the thiazoline acid derivatives are useful in diagnosing and treating pathological conditions associated with an excess of trivalent metals in humans and animals.

  本发明涉及一种新型噻唑酮酸及其衍生物，可用作治疗应用中三价金属的螯合剂。例如，这些噻唑酮酸衍生物可用于诊断和治疗与人类和动物体内三价金属过量相关的病理状况。
• Antimalarial agents
  申请人：UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

  公开号：EP1488791A2

  公开（公告）日：2004-12-22

  Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically effective amount of a compound of formula (I) or (IV), i.e., sufficient quantity to reduce the population of Plasmodium. The composition of the invention is a compound of formula (I) or (IV) with a pharmaceutical excipient. The article of manufacture is the composition in combination with labelling for treating malaria. The substituents are detailed in the specification.

  本发明描述了用于治疗原生动物疟原虫感染的人类疟疾的组合物、制造品和方法。该方法包括施用治疗有效量的式（I）或（IV）化合物，即足以减少疟原虫数量的量。本发明的组合物是含有药用赋形剂的式 (I) 或 (IV) 化合物。制成品是该组合物与用于治疗疟疾的标签相结合。取代基详见说明书。
• Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
  申请人：Gurtner C. Geoffrey

  公开号：US20060100189A1

  公开（公告）日：2006-05-11

  One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed.

  本发明的一个方面涉及一种治疗或预防受试者急性高血糖和/或脂肪酸通量增加的病理后遗症的方法。该方法包括向受试者施用 ROS 抑制剂。此外，还公开了促进新生血管生成、抑制氧化或游离脂肪酸过度释放的方法，以及鉴定适合治疗或预防 ROS 介导的损伤的化合物的方法。
• Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators
  作者：Raymond J. Bergeron、Jan Wiegand、William R. Weimar、J. R. Timothy Vinson、Jörg Bussenius、Guo Wei Yao、James S. McManis

  DOI：10.1021/jm980340j

  日期：1999.1.1

  Further structure-activity studies of desferrithiocin analogues are carried out. (S)-desazadesmethyldesferrithiocin, 2-(2-hydroxyphenyl)-Delta(2)-thiazoline-4(S)-carboxylic acid, serves as the principal framework in the current paper. Desazadesmethyldesferrithiocin can be structurally altered with facility, and data are already available on its iron-clearing properties and toxicity parameters. Four different kinds of structural modifications of this framework are undertaken: introduction of hydroxy, carboxy, or methoxy groups on the aromatic ring; alteration of the thiazoline ring; increasing the distance between the ligand donor atoms; and benz-fusion of the aromatic rings. The structural modifications described are shown to have a tremendous imp act on both the iron clearance and toxicity profiles of the desazadesmethyldesferrithiocin molecule. All of the compounds are assessed in a bile-duct-cannulated rodent model to determine iron clearance efficiency. Ligands which demonstrate an efficiency of greater than 2% are carried forward to the iron-overloaded primate for iron-clearing measurements. Ligands with efficiencies greater than 3% in the primate are then evaluated in a formal toxicity study in rodents. On the basis of the results of the present work, 2-(2,4-dihydroxyphenyl)-Delta(2)-thiazoline-4(S)-carboxylic acid is a promising candidate for clinical evaluation.
• US06083966
  申请人：——

  公开号：——

  公开（公告）日：——